Updates on the cytogenetics and molecular genetics 832 of bone and soft tissue tumors, Mesothelioma. Cancer Genet Cytogenet, vol.127, issue.2, pp.93-110, 2001. ,
Cytogenetic and molecular genetic 834 changes in malignant mesothelioma, Cancer Genet Cytogenet, vol.170, issue.1, pp.9-15, 2006. ,
Genomic abnormalities and signal transduction dysregulation in 836 malignant mesothelioma cells, Cancer Sci, vol.101, issue.1, pp.1-6, 2010. ,
Chromosome 838 changes in malignant mesothelioma, Cancer Genet Cytogenet, vol.20, issue.3-4, pp.191-201, 1986. ,
Cytogenetic analysis of 840 malignant mesothelioma, Cancer Genet Cytogenet, vol.47, issue.1, pp.1-28, 1990. ,
Molecular cytogenetic 842 differences between histological subtypes of malignant mesotheliomas: DNA cytometry and 843 comparative genomic hybridization of 90 cases, J Pathol, vol.197, issue.3, pp.363-371, 2002. ,
Gene copy number analysis 845 in malignant pleural mesothelioma using oligonucleotide array CGH, Cytogenet Genome Res, vol.846, issue.1-2, pp.46-52, 2007. ,
Genomic profiling of malignant pleural 848 mesothelioma with array-based comparative genomic hybridization shows frequent non-849 random chromosomal alteration regions including JUN amplification on 1p32, Cancer Sci, vol.850, issue.3, pp.438-446, 2007. ,
Genomic events associated with ,
The promyelocytic 854 leukemia zinc-finger gene, PLZF, is frequently downregulated in malignant mesothelioma 855 cells and contributes to cell survival, Oncogene, vol.29, issue.11, pp.1633-1640, 2010. ,
Integrated profiling reveals a 857 global correlation between epigenetic and genetic alterations in mesothelioma, Cancer Res, vol.858, issue.14, pp.5686-5694, 2010. ,
Syntenic Relationships between Genomic 860 Profiles of Fiber-Induced Murine and Human Malignant Mesothelioma, Am J Pathol, vol.861, issue.2, pp.881-894, 2011. ,
Second generation sequencing of the 863 mesothelioma tumor genome, PLoS One, vol.5, issue.5, p.10612, 2010. ,
Asbestos-associated chromosomal 865 changes in human mesothelial cells, Proc Natl Acad Sci U S A, vol.82, issue.11, pp.3884-3888, 1985. ,
Do asbestos and carbon 867 nanotubes pose the same health risk?, Part Fibre Toxicol, vol.6, p.16, 2009. ,
,
, Chromosomal abnormalities and their correlations with asbestos exposure and survival in 870 patients with mesothelioma, Br J Cancer, vol.60, issue.4, pp.618-626, 1989.
Malignant mesothelioma: clinical 872 characteristics, asbestos mineralogy and chromosomal abnormalities of 41 patients, Eur J 873 Cancer, vol.28, issue.8-9, pp.1373-1379, 1992. ,
The use of CDKN2A deletion 875 as a diagnostic marker for malignant mesothelioma in body cavity effusions, Cancer, vol.876, issue.1, pp.51-56, 2003. ,
9p21 deletion in the diagnosis of 996 malignant mesothelioma, using fluorescence in situ hybridization analysis, Pathol Int, vol.997, issue.5, pp.395-399, 2010. ,
p16 alterations and deletion mapping 999 of 9p21-p22 in malignant mesothelioma, Cancer Res, vol.54, issue.21, pp.5547-5551, 1994. ,
Immunohistochemical analysis of 1001 the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma, J Natl Cancer, p.1002 ,
, , vol.87, pp.1870-1875, 1995.
Implications of P16/CDKN2A deletion in pleural mesotheliomas ,
, Lung Cancer, vol.49, issue.1, pp.95-98, 2005.
Prognostic significance of p16/cdkn2a loss 1006 in pleural malignant mesotheliomas, Virchows Arch, vol.453, issue.6, pp.627-635, 2008. ,
Genetic alteration of the beta-catenin ,
, gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a 1009 new 3p21.3 homozygous deletion, Oncogene, vol.20, issue.31, pp.4249-4257, 2001.
Wnt pathway activation in 1011 mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-1012 catenin, Cancer Res, vol.63, issue.15, pp.4547-4551, 2003. ,
In arrayed ranks: array technology 1014 in the study of mesothelioma, J Thorac Oncol, vol.4, issue.3, pp.411-425, 2009. ,
Gene expression profiling of 1016 malignant mesothelioma cell lines : cDNA array study, Int J Cancer, vol.91, issue.4, pp.492-496, 2001. ,
Cell protection, 1018 resistance and invasiveness of two malignant mesotheliomas as assessed by 10K-microarray ,
Microdissection, mRNA amplification and 1021 microarray: a study of pleural mesothelial and malignant mesothelioma cells, Biochimie, vol.1022, issue.1, pp.13-19, 2004. ,
Identification of novel candidate 1027 oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale 1028 transcriptional profiling, Carcinogenesis, vol.10, issue.1, pp.1827-1840, 1026. ,
Gene expression profiling of 1030 malignant mesothelioma, Clin Cancer Res, vol.9, issue.8, pp.3080-3097, 2003. ,
Global gene expression profiling of 1032 human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as 1033 potential tumour target, Am J Pathol, vol.4, issue.9, pp.762-770, 1036. ,
Mechanisms of FUS1/TUSC2 1038 deficiency in mesothelioma and its tumorigenic transcriptional effects, Mol Cancer, vol.1039, p.80, 2009. ,
Gene expression profiling identifies 1041 matriptase overexpression in malignant mesothelioma, J Natl Cancer Inst, vol.125, issue.5, pp.598-605, 2003. ,
Four-gene expression ratio test for 1048 survival in patients undergoing surgery for mesothelioma, J Natl Cancer Inst, vol.11, issue.12, pp.678-686, 1047. ,
Microarray analysis identifies a 1051 death-from-cancer signature predicting therapy failure in patients with multiple types of 1052 cancer, J Clin Invest, vol.115, issue.6, pp.1503-1521, 2005. ,
Protumorigenic role of HAPLN1 1056 and its IgV domain in malignant pleural mesothelioma, Clin Cancer Res, vol.70, issue.3, p.87, 1055. ,
Meta-analysis of several gene lists for distinct types of cancer: 1059 A simple way to reveal common prognostic markers, BMC Bioinformatics, vol.8, issue.1, 2007. ,
, Malignant pleural mesothelioma: genome-wide expression patterns reflecting general 1062 resistance mechanisms and a proposal of novel targets, Lung Cancer, vol.67, issue.1, pp.57-68, 2010.
Cell signaling by receptor tyrosine kinases, Cell, vol.141, issue.7, pp.1117-1134, 1064. ,
EGFR 1066 expression: associations with outcome and clinicopathological variables in malignant pleural 1067 mesothelioma, Lung Cancer, vol.54, issue.3, pp.399-407, 2006. ,
EGFR and PDGFR 1069 differentially promote growth in malignant epithelioid mesothelioma of short and long term 1070 survivors, Thorax, vol.63, issue.4, pp.345-351, 2008. ,
EGFR overexpression in malignant 1072 pleural mesothelioma. An immunohistochemical and molecular study with clinico-1073 pathological correlations, Lung Cancer, vol.51, issue.2, pp.207-215, 2006. ,
Targeted epidermal growth factor receptor 1075 therapy in malignant pleural mesothelioma: Where do we stand? Cancer Treat Rev, Clin Cancer, vol.94, p.1078, 1076. ,
, Res, vol.11, issue.6, pp.2300-2304, 2005.
Phase II study of erlotinib in patients 1083 with malignant pleural mesothelioma: a Southwest Oncology Group Study, J Clin Oncol, vol.113, issue.4, pp.2406-2413, 2007. ,
The spectrum of ,
, Kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using a single-1087 source antibody with a review of the literature, Arch Pathol Lab Med, vol.128, issue.5, pp.538-543, 2004.
c-Kit is not 1089 expressed in malignant mesothelioma, Mod Pathol, vol.16, issue.8, pp.818-822, 2003. ,
Update on the molecular biology of 1091 malignant mesothelioma, Cancer, vol.109, issue.8, pp.1454-1461, 2007. ,
,
, Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta 1094 expression, J Pathol, vol.189, issue.1, pp.72-78, 1999.
Expression of vascular endothelial growth 1096 factor in malignant mesothelioma, Anticancer Res, vol.26, issue.6C, pp.4833-4836, 2006. ,
Prognostic significance of vascular 1098 endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural 1099 mesothelioma, Chest, vol.128, issue.5, pp.3382-3387, 2005. ,
VEGF and VEGF type C play an 1101 important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma 1102 tumours, Br J Cancer, vol.81, issue.1, pp.54-61, 1999. ,
Co-expression of vascular 1104 endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma ,
, Respiration, vol.67, issue.1, pp.36-40, 2000.
Vascular endothelial growth factor is an 1107 autocrine growth factor in human malignant mesothelioma, J Pathol, vol.193, issue.4, pp.468-475, 2001. ,
,
, Immunohistochemical expression and distribution of VEGFR-3 in malignant mesothelioma
, Diagn Cytopathol, vol.35, issue.12, pp.786-791, 2007.
Malignant mesothelioma growth inhibition 1112 by agents that target the VEGF and VEGF-C autocrine loops, Int J Cancer, vol.104, issue.5, p.610, 2003. ,
5-lipoxygenase regulates malignant 1115 mesothelial cell survival: involvement of vascular endothelial growth factor, FASEB J. Page, vol.49 ,
Molecular targets in malignant pleural mesothelioma 1118 treatment, Curr Drug Targets, vol.10, issue.12, pp.1235-1244, 2009. ,
Comparison of production of 1120 transforming growth factor-beta and platelet-derived growth factor by normal human 1121 mesothelial cells and mesothelioma cell lines, Cancer Res, vol.47, issue.23, pp.6180-6184, 1987. ,
Human malignant 1123 mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial 1124 cells express predominantly PDGF alpha-receptors, Oncogene, vol.6, issue.11, pp.2005-2011, 1991. ,
,
, Immunoreactivity for the beta chain of the platelet-derived growth factor receptor in 1127 malignant mesothelioma and non-neoplastic mesothelium, J Pathol, vol.167, issue.1, pp.1-4, 1992.
ERK1/2 and p38 MAP kinase 1129 control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison 1130 between mesothelioma and mesothelial cells, J Cell Physiol, vol.207, issue.2, pp.540-552, 2006. ,
The PDGF family: four gene products form 1132 five dimeric isoforms, Cytokine Growth Factor Rev, vol.15, issue.4, pp.197-204, 2004. ,
Characterization of 1134 the molecular mechanism involved in the activation of hyaluronan synthetase by platelet-1135 derived growth factor in human mesothelial cells, Biochem J, vol.283, pp.165-170, 1992. ,
Expression of human 1137 hyaluronan synthases in response to external stimuli, Biochem J, vol.348, pp.29-35, 2000. ,
,
, Tumorigenic conversion of human mesothelial cells as a consequence of platelet-derived 1140 growth factor-A chain overexpression, Am J Respir Cell Mol Biol, vol.8, issue.2, pp.214-221, 1993.
,
, Paradoxical effects of platelet-derived growth factor-A overexpression in malignant 1143 mesothelioma. Antiproliferative effects in vitro and tumorigenic stimulation in vivo, Am J, p.1144
, Respir Cell Mol Biol, vol.24, issue.6, pp.694-702, 2001.
Limited efficacy of imatinib 1146 mesylate in malignant mesothelioma: a phase II trial, Lung Cancer, vol.50, issue.1, pp.83-86, 2005. ,
Negative results of an Italian Group for 1148 ,
Me.) pilot study of single-agent imatinib mesylate in malignant pleural 1149 mesothelioma, Cancer Chemother Pharmacol, vol.59, issue.1, pp.149-150, 2007. ,
Molecular pathways in malignant pleural 1151 mesothelioma, Cancer Lett, vol.239, issue.2, pp.183-189, 2006. ,
,
, Textbook of pleural diseases, pp.27-37, 2008.
Selective activation of insulin receptor 1155 substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant 1156 phenotypes, Cancer Res, vol.64, issue.20, pp.7479-7485, 2004. ,
Normal human mesothelial cells and 1158 mesothelioma cell lines express insulin-like growth factor I and associated molecules ,
, , vol.53, pp.2858-2864, 1993.
Regulation of matrix metalloprotease activity in malignant 1161 mesothelioma cell lines by growth factors, Thorax, vol.58, issue.3, pp.198-203, 2003. ,
Combined inhibition of MET 1163 and EGFR suppresses proliferation of malignant mesothelioma cells, Carcinogenesis, vol.1164, issue.7, pp.1097-1105, 2009. ,
, , p.1166
, Met/hepatocyte growth factor pathway in malignant pleural mesothelioma, Cancer Res, vol.1167, issue.1, pp.352-361, 2006.
Hepatocyte 1169 growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an 1170 increased microvessel density in malignant pleural mesothelioma, J Cancer Res Clin Oncol, vol.1171, issue.6, pp.291-296, 1998. ,
Immunoreactivity for 1173 cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas, Histopathology, vol.36, issue.6, pp.522-528, 1174. ,
Expression of HGF/SF in mesothelioma 1176 cell lines and its effects on cell motility, proliferation and morphology, Br J Cancer, vol.1177, issue.7, pp.1052-1059, 1998. ,
Inhibition of the met receptor in 1179 mesothelioma, Clin Cancer Res, vol.11, issue.22, pp.8122-8130, 2005. ,
Phosphorylated extracellular 1181 signal-regulated kinases are significantly increased in malignant mesothelioma, J Histochem, p.1182 ,
, Cytochem, vol.54, issue.8, pp.855-861, 2006.
Mitogen-activated 1184 protein kinase expression and activation does not differentiate benign from malignant 1185 mesothelial cells, Cancer, vol.103, issue.11, pp.2427-2433, 2005. ,
Arsenic trioxide induces apoptosis 1187 through JNK and ERK in human mesothelioma cells, J Cell Physiol, vol.226, issue.3, pp.762-768, 2011. ,
Targeted inhibition of multiple receptor Page 52 ,
Mesothelioma cells escape heat stress 1191 by upregulating Hsp40/Hsp70 expression via mitogen-activated protein kinases, J Biomed, p.1192 ,
, Biotechnol, p.451084, 2009.
PTEN/MMAC1/TEP1 in signal 1194 transduction and tumorigenesis, Eur J Biochem, vol.263, issue.3, pp.605-611, 1999. ,
Malignant pleural mesothelioma 1196 cells resist anoikis as quiescent pluricellular aggregates. Cell Death and Differentiation, vol.16, pp.1146-1155, 1197. ,
Human and mouse mesotheliomas 1199 exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor 1200 cell growth, Oncogene, vol.24, issue.40, pp.6080-6089, 2005. ,
Activation of the PI3K-AKT 1202 pathway in human malignant mesothelioma cells, Molecular Medicine Reports, vol.2, issue.2, pp.181-188, 1203. ,
PTEN expression is a strong 1205 predictor of survival in mesothelioma patients, Eur J Cardiothorac Surg, vol.33, issue.3, pp.502-506, 2008. ,
Wnt/beta-catenin signaling in development and disease, Cell, vol.127, issue.3, pp.469-480, 1207. ,
Dickkopf-1 antagonizes Wnt signaling 1209 independent of beta-catenin in human mesothelioma, Biochem Biophys Res Commun, vol.323, issue.4, pp.1246-1250, 1210. ,
Wnt2 as a new therapeutic target in malignant 1212 pleural mesothelioma, Int J Cancer, vol.117, issue.2, pp.326-332, 2005. ,
Down-regulation of inhibition of 1214 differentiation-1 via activation of activating transcription factor 3 and Smad regulates ,
, REIC/Dickkopf-3-induced apoptosis, Cancer Res, vol.68, issue.20, pp.8333-8341, 2008.
YAP1 is involved in mesothelioma 1217 development and negatively regulated by Merlin through phosphorylation, Carcinogenesis, vol.29, issue.11, pp.2139-2146, 1218. ,
LATS2 Is a Tumor Suppressor ,
, Gene of Malignant Mesothelioma. Cancer Res, vol.71, issue.3, pp.873-883, 2011.
,
, Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer, vol.64, pp.140-147, 1223.
The NF2 tumor suppressor gene product, p.1225 ,
, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 1226 expression, Mol Cell Biol, vol.25, issue.6, pp.2384-2394, 2005.
Re-1228 expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells 1229 and negatively regulates FAK, Oncogene, vol.25, issue.44, pp.5960-5968, 2006. ,
Loss of the 1231 tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent 1232 mTORC1 signaling, Mol Cell Biol, vol.29, issue.15, pp.4235-4249, 2009. ,
Human Fas-associated factor 1, 1234 interacting with ubiquitinated proteins and valosin-containing protein, is involved in the 1235 ubiquitin-proteasome pathway, Mol Cell Biol, vol.25, issue.6, pp.2511-2524, 2005. ,
Activated TNF-alpha/NF-kappaB 1237 signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas 1238 from Arf knockout mice, Proc Natl Acad Sci, vol.106, issue.9, pp.3420-3425, 2009. ,
,
, Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome 1241 pathway as a therapeutic target in poor prognosis tumors, Oncogene, vol.26, issue.4, pp.610-617, 2007.
Molecular characterization of tumour 1243 heterogeneity and malignant mesothelioma cell differentiation by gene profiling, J Pathol, vol.207, issue.1, pp.91-101, 1244. ,
Bortezomib inhibits nuclear 1246 factor-kappaB dependent survival and has potent in vivo activity in mesothelioma, p.1247 ,
, Cancer Res, vol.13, pp.5942-5951, 2007.
Proteasome inhibitor PSI induces 1249 apoptosis in human mesothelioma cells, Cancer Lett, vol.232, issue.2, pp.161-169, 2006. ,
, Proteasome Inhibitor, vol.132, p.1251
, Apoptosis and Inhibits Invasion of Human Malignant Pleural Mesothelioma Cells
, Oncol, vol.1, issue.3, pp.129-140, 2008.
Preclinical studies of the proteasome 1254 inhibitor bortezomib in malignant pleural mesothelioma, Cancer Chemother Pharmacol, vol.1255, issue.4, pp.549-558, 2008. ,
Mammalian target 1257 of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma 1258 multicellular spheroids, J Biol Chem, vol.283, pp.13021-11330, 2008. ,
Re-expression of p16INK4a in mesothelioma 1260 cells results in cell cycle arrest, cell death, tumor suppression and tumor regression ,
, Oncogene, vol.16, issue.24, pp.3087-3095, 1998.
Adenovirus-mediated p14ARF gene transfer in 1263 human mesothelioma cells, J Natl Cancer Inst, vol.92, issue.8, pp.636-641, 2000. ,
p14ARF 1265 modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53 ,
, Cancer Res, vol.61, issue.16, pp.5959-5963, 2001.
Inhibition of survivin and aurora B 1268 kinase sensitizes mesothelioma cells by enhancing mitotic arrests, Int J Radiat Oncol Biol, p.1269 ,
, Phys, vol.67, issue.5, pp.1519-1525, 2007.
Stathmin is overexpressed in malignant 1271 mesothelioma, Anticancer Res, vol.27, issue.1A, pp.39-44, 2007. ,
The mesothelial keratins: a new family of 1273 cytoskeletal proteins identified in cultured mesothelial cells and nonkeratinizing epithelia ,
, Cell, vol.31, issue.3, pp.693-703, 1982.
Cell cycle checkpoint status in human 1276 malignant mesothelioma cell lines: response to gamma radiation, Br J Cancer, vol.1277, issue.3, pp.388-395, 2003. ,
Suppression 1279 of the mouse double minute 4 gene causes changes in cell cycle control in a human 1280 mesothelial cell line responsive to ultraviolet radiation exposure, Environ Mol Mutagen, vol.50, issue.9, pp.753-759, 1281. ,
Malignant mesothelioma, Lancet ,
Evaluation 1285 of apoptosis and immunohistochemical expression of the apoptosis-related proteins in 1286 mesothelioma, Hiroshima J Med Sci, vol.59, issue.2, pp.27-33, 2010. ,
Apoptosis and lung injury, Keio J Med, vol.54, issue.4, pp.184-189, 1288. ,
Tumor necrosis 1290 factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in 1291 mesothelioma cell lines, Am J Respir Cell Mol Biol, vol.25, issue.1, pp.111-118, 2001. ,
FLIP overexpression inhibits death 1293 receptor-induced apoptosis in malignant mesothelial cells, Oncogene, vol.23, issue.47, pp.7753-1294, 2004. ,
Alpha-tocopheryl succinate and 1296 TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma 1297 cells, Br J Cancer, vol.90, issue.8, pp.1644-1653, 2004. ,
Malignant mesothelioma 1299 cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim ,
, Mol Cancer Ther, vol.6, issue.10, pp.2766-2776, 2007.
Sensitization of 1302 mesothelioma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced 1303 apoptosis by heat stress via the inhibition of the 3-phosphoinositide-dependent kinase 1/Akt 1304 pathway, Cancer Res, vol.67, issue.6, pp.2865-2871, 2007. ,
Sorafenib inhibits ERK1/2 and MCL-1(L) 1306 phosphorylation levels resulting in caspase-independent cell death in malignant pleural 1307 mesothelioma, Cancer Biol Ther, vol.8, issue.24, pp.2406-2416, 2009. ,
mTOR mediates survival signals in 1309 malignant mesothelioma grown as tumor fragment spheroids, Am J Respir Cell Mol Biol, vol.39, issue.5, pp.576-583, 1310. ,
,
, Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in 1313 malignant mesothelioma, Clin Cancer Res, vol.5, issue.11, pp.3508-3515, 1999.
Antisense therapy for 1315 malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product, J Thorac, p.1316 ,
, Cardiovasc Surg, vol.123, issue.6, pp.1191-1198, 2002.
Bcl2/bcl-1318 xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma, Cancer, vol.1319 ,
, Biol Ther, vol.6, issue.2, pp.246-252, 2007.
Bcl-xL antisense oligonucleotide and 1321 cisplatin combination therapy extends survival in SCID mice with established mesothelioma 1322 xenografts, Int J Cancer, vol.123, issue.1, pp.202-208, 2008. ,
Downregulation of Bcl-xL and Mcl-1 is 1324 sufficient to induce cell death in mesothelioma cells highly refractory to conventional 1325 chemotherapy, Carcinogenesis, vol.31, issue.6, pp.984-993, 2010. ,
,
, Expression of bcl-2 family members in malignant pleural mesothelioma, Acta Oncol, vol.45, issue.4, pp.449-453, 1328.
Induction of apoptosis in mesothelioma cells by 1330 antisurvivin oligonucleotides, Mol Cancer Ther, vol.1, issue.9, pp.687-694, 2002. ,
Survivin is highly expressed and 1332 promotes cell survival in malignant peritoneal mesothelioma, Cell Oncol, vol.29, issue.6, pp.453-1333, 2007. ,
Expression of 1335 inhibitor-of-apoptosis protein family members in malignant mesothelioma, Hum Pathol, vol.38, issue.7, pp.986-994, 1336. ,
A histone 1338 deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely 1339 responsible for increased apoptosis with TRAIL, J Thorac Oncol, vol.4, issue.2, pp.149-160, 2009. ,
Telomerase 1341 activity in human pleural mesothelioma, Thorax, vol.53, issue.11, pp.915-918, 1998. ,
Multiple mechanisms of telomere 1343 maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal 1344 mesothelioma, Clin Cancer Res, vol.14, issue.13, pp.4134-4140, 2008. ,
Methionine 1346 aminopeptidase-2 regulates human mesothelioma cell survival. Role of Bcl-2 expression and 1347 telomerase activity, Am J Pathol, vol.159, issue.2, pp.721-731, 2001. ,
National Mesothelioma Virtual 1349 Bank: a standard based biospecimen and clinical data resource to enhance translational 1350 research, BMC Cancer, vol.8, p.236, 2008. ,